JAMES B. BREITMEYER - 14 Feb 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
14 Feb 2024
Net transactions value
$0
Form type
4
Filing time
15 Feb 2024, 18:00:26 UTC
Previous filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +28,400 $0.000000 28,400 14 Feb 2024 Common Stock 28,400 $9.18 Direct F1
transaction ONCT Stock Option Award $0 +6,200 $0.000000 6,200 14 Feb 2024 Common Stock 6,200 $9.18 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.